Related Experiment Video
Updated: Jul 2, 2026
08:58
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Adiponectin and alcoholic fatty liver disease
Christopher Q Rogers1, Joanne M Ajmo, Min You
1Department of Molecular Pharmacology and Physiology, University of South Florida Health Sciences Center,Tampa, FL 33612, USA.
IUBMB Life
|August 19, 2008
Summary
Adiponectin protects against alcoholic fatty liver disease by enhancing fat oxidation and reducing lipid synthesis. Modulating adiponectin and its receptors offers potential therapeutic strategies for AFLD.
Area of Science:
- Hepatology
- Endocrinology
- Molecular Biology
Background:
- Alcoholic fatty liver disease (AFLD) is a prevalent chronic condition.
- Ethanol impairs lipid metabolism via transcriptional regulators like AMPK, SIRT1, and PPARalpha.
- Adiponectin, an adipose hormone, and its receptors (AdipoRs) are implicated in AFLD development.
Purpose of the Study:
- To review the role of adiponectin and AdipoRs in liver lipid homeostasis.
- To emphasize the relationship between adiponectin and alcoholic liver steatosis.
- To discuss adiponectin's protective mechanisms and therapeutic potential for AFLD.
Main Methods:
- Literature review focusing on adiponectin, its receptors, and alcoholic liver steatosis.
- Analysis of molecular mechanisms underlying ethanol-induced hepatic steatosis.
- Examination of signaling pathways involved in adiponectin's protective effects.
Main Results:
- Altered adiponectin and AdipoR expression correlate with alcoholic liver steatosis in rodent models.
- Adiponectin demonstrates a protective role against AFLD.
- Adiponectin's effects are mediated by enhanced fat oxidation and reduced lipid synthesis.
Conclusions:
- Adiponectin plays a crucial role in preventing hepatic steatosis.
- Nutritional and pharmacological strategies targeting adiponectin may treat AFLD.
- Further research into adiponectin signaling pathways is warranted for therapeutic development.
Related Concept Videos
01:21Chronic Pancreatitis II: Pathophysiology
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:25Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...